News
June 18, 2019

Regenstrief scientist explains how class of drugs may be related to dementia

Regenstrief research scientist Noll Campbell, PharmD, M.S., spoke about a common class of drugs and how it affects the brain on an Indianapolis radio show.

Dr. Campbell was a guest on Caregiver Crossing, which airs every Saturday on 93.1 WIBC. Dr. Campbell addressed the topic of anticholinergics and their potential link to Alzheimer’s and dementia. Anticholinergics are a common class of drug that includes some allergy medications, sleeping pills and many more common medicines.

Dr. Campbell recently received a $3.3 million grant from the National Institute on Aging to conduct the first clinical trial designed to determine if stopping these medications results in sustained improvements in cognition.

Listen to his discussion with the Caregiver Crossing hosts and his advice for people who are taking these medications.

Segment 1

Segment 2

Click here for more information on Caregiver Crossing.

  • Noll Campbell, PharmD, MS

Related News

(From left to right) Dr. Brian Dixon, Dr. Sanji De Sylva and Isaac Vetter. Photo credit: Svetlana Efimova

Regenstrief experts advance global dialogue on digital health and interoperability at forum in Dubai

Regenstrief informaticians joined global leaders who shared their expertise at the 8th ZIMAM Digital Health Forum November 5-6, in

Regenstrief researchers join national stage to advance aging and gerontology research

Regenstrief Institute research scientists joined leading experts from across the nation at the Gerontological Society of America (GSA) 2025

illustration of the combination of interventions used in the D3 pragmatic clinical trial

Zero-cost, AI-driven digital detection identifies Alzheimer’s and related dementias without additional clinician time

Few primary care practices are designed for the timely detection of Alzheimer’s disease and related dementias. The limited time